Focus: RadioMedix is a radiopharmaceutical and imaging technology company headquartered in Houston, TX, focused on oncology and nephrology applications. The company operates as a public entity with a specialized pipeline in nuclear medicine and related manufacturing.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Stable — net +1 jobs in 30d
1 added, 0 removed. Backfill posture.
RadioMedix offers specialized radiopharmaceutical expertise in an emerging modality, but thin hiring, opaque financial metrics, and limited public visibility create uncertainty around career growth and company momentum.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for RadioMedix
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from RadioMedix's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it. - Pharma Voice
One doctor helped kickstart US nuclear medicine’s new wave. Now he’s refining it. Pharma Voice
Radiomedix bets on alpha emitters for radiopharma’s future - BioWorld News
Radiomedix bets on alpha emitters for radiopharma’s future BioWorld News
Based on last 3 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Toward Integrated Independence: Johannes Czernin Discusses the Future of Theranostics with Ebrahim Delpassand, Eric Rohren, and Wolfgang Weber.
Targeted α-Emitter Therapy with (212)Pb-DOTAMTATE for the Treatment of Metastatic SSTR-Expressing Neuroendocrine Tumors: First-in-Humans Dose-Escalation Clinical Trial.
Showing 5 of 10 publications
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo